一品红：全资子公司芩香清解口服液获得药物临床试验

Core Viewpoint - The announcement indicates that Yipinhong's subsidiary, Yipinhong Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of Qinxiangqing Jie Oral Solution, aimed at treating acute upper respiratory infections in adults with specific symptoms [1]. Group 1 - Yipinhong's subsidiary has been granted a clinical trial approval for Qinxiangqing Jie Oral Solution [1]. - The clinical trial will focus on adults suffering from acute upper respiratory infections characterized by both internal and external heat symptoms [1]. - The application for the clinical trial was a supplementary submission aimed at refining the clinical trial protocol and expanding the target population [1].